News

News

New VP- Business Development at IRICoR

IRICoR is very pleased to announce the appointmentas of June 2, 2022 of Claude Larose, as Vice-President, Business Development and new member of IRICoR’s Management team. In this role, Mr. Larose will be primarily responsible for establishing links and concluding agreements with entities outside IRICoR, both in the public and private sectors, with a view to exit events for projects […]

2022 BIO International Convention is back in person!

IRICoR announces its participation in the BIO 2022 international convention to be held from June 13 to 16, 2022 in San Diego. This industry event aims to create business opportunities among life science players from all over the world. It is also an opportunity for companies and institutions to develop partnerships of interest with complementary organizations, in particular through the […]

IRICoR will attend the AUTM Canadian Region Meeting

 
IRICoR attend the AUTM Canadian Region Meeting, May 16-18, 2022.
AUTM’s Regional Meeting invites technology transfer professionals from around the globe to network, make deals and gain valuable insights from world-class speakers and panels.
If you would like to meet with IRICoR at AUTM 2022, please contact Jean-louis Brochu, M.Sc., Senior Intellectual Property Manager, who will represent IRICoR at this event:

By email : 

Unveiling of the Stratégie québécoise des sciences de la vie 2022-2025

As part of Effervescence, an event organized by Montréal Invivo and bringing together major players in the life sciences community, Pierre Fitzgibbon Minister of Economy and Innovation presented the Stratégie québécoise des sciences de la vie 2022-2025

IRICoR is delighted with this announcement. Challenged by COVID-19, stakeholders in the sector have mobilized and adapted to respond to the health crisis, and […]

Epitopea raises seed financing – $ 14M

IRICoR is delighted with the announcement made today by Epitopea, a transatlantic cancer immunotherapeutics company, on a $13.6M seed investment from a transatlantic syndicate of top-tier life sciences investors, including AdventLifeSciences, CTI Life Sciences, Cambridge Innovation Capital (CIC) and Fonds de solidarité FTQ.
The company’s proprietary technology provides an innovative approach to identifying shared, aberrantly expressed tumour specific antigens, known as […]

A new agreement for an international public-private research collaboration in drug discovery

IRICoR is delighted with the announcement made today by ONO Pharmaceutical Co., Ltd. (“ONO”), one of Japan’s largest clinical-stage pharmaceutical companies, on signing a collaboration agreement with Domain Therapeutics S.A. (“Domain”) and University of Montreal (“UdeM”), to discover new small molecules targeting G protein-coupled receptors (GPCRs) in the treatment of a metabolic disease.
“Very early on, we identified and supported this […]

Webinar IP

 
Aimed at research and life sciences professionals, IRICoR is very excited to invite you to its next workshop on intellectual property.
 
To mark World Intellectual Property Day, please join us on April 26, from 12:00 pm to 1:30 pm, during lunch break for this webinar on intellectual property, entitled: Patents: practical and strategic considerations
 
Our guest speaker, Mr. Alain Dumont, […]

IVADO interviewe Nadine Beauger

It is with pleasure that Mrs. Nadine Beauger, President and CEO of IRICoR, went “Under the microscope” of IVADO. “Under the microscope” is a project aimed at highlighting members of its community through short portraits.
Extract from the interview: “Our flexible project development model allows us to identify complementary expertise to include artificial intelligence know-how in drug discovery projects.”
Read the interview […]

The Making of Epitopea, a New Transatlantic Cancer Immunotherapeutics Venture

Sessions have been announced for the 7th annual Access to Innovation Conference. The virtual conference brings together all stakeholders in the life sciences sector, academia, research, health institutions, and government to share their insights into this year’s theme: Building on Excellence: A Vibrant Future for BC Life Sciences.
We are pleased to announce that IRICoR is a partner […]

Premières en affaires magazine

 
The new issue of Premières en affaires magazine is now available. IRICoR is proud to have collaborated on this edition.
 
Nadine Beauger, President and CEO of IRICoR and Anne Marinier, Director of Medicinal Chemistry and Director of the Drug Discovery Unit at IRIC, highlight the strength of a collaborative women and the importance of combining science and business, for the ultimate […]

Next Page »

© 2008-2022 IRICoR